Congratulations Jonathan! 🥳

See our timeline of prostate cancer research achievements here ⤵️

www.icr.ac.uk/research-and...

to being the first internationally to treat prostate cancer patients with a new, more precise form of radiotherapy in 2000, and recently showing that a simple at-home spit test is more accurate at identifying future risk of prostate cancer for some men.

From the discovery and subsequent development of #Abiraterone in the 1990s – the first treatment ever shown to be effective in men with advanced prostate cancer -

Read our special feature here ⬇️

From the early development of PARP and aromatase inhibitors to cutting-edge advances in liquid biopsy, immunology and genomics – the centre continues to lead the way in turning scientific discovery into real impact for patients.

Our new blog takes you behind the scenes of that milestone – exploring how the centre came to be, the discoveries that have defined its first 25 years and the researchers driving progress for the future.

Ultimately, this work brings us closer to understanding why outcomes differ between men and women – and to developing more personalised, effective treatments for all patients with AML.

More from us here ⬇️

By ruling out a previously plausible explanation, the research helps focus efforts on more promising areas – from drug metabolism to immune responses – and highlights the importance of considering sex as a biological variable in future AML research and clinical trial design.

The study found that while AML cells express high levels of androgen receptors, these receptors don’t appear to influence how the cancer grows or responds to treatment. Instead, inflammation and immune signalling may play a bigger role.

In addition to preventing the need for amputations, this new treatment combination could help stop cancer spreading and even prime treatment-resistant tumours to respond to immunotherapy.

Read more ⬇️

Our researchers showed that delivering a cancer-fighting virus alongside isolated limb perfusion triggered a whole-body immune response rather than just a localised one in the affected limb. They also found this approach to be well-tolerated and, for some patients, very effective.

Dr Amin Mirza shares how these complementary technologies help our scientists to characterise new compounds, understand how they interact with biological targets and identify those with the potential to become treatments.

From weighing molecules with extraordinary precision to visualising their atomic structures, our scientists are harnessing cutting-edge chemical analysis tools to accelerate drug discovery from lab bench to bedside.

Read more about Sir Bob Champion's incredible work here ⬇️

@helink.bsky.social, Chief Executive of the ICR said,
“We warmly congratulate Bob on this well-deserved honour and thank him for his generous support over the years - both in raising vital funds and championing the importance of our life-changing work.”

Soft tissue sarcomas have historically been very difficult to treat. However, this new research suggests that by exploiting the cancer’s own resistance evolutions, we may be able to steer it towards drug-sensitive states, making treatment more effective.